We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 or complete the questionnaire at this link to be contacted about future studies.
Comparing Fingerstick Blood Glucose Monitoring versus Continuous Glucose Monitoring in Primary Care (The “GluCoCare” Study: GLUcose monitoring COmparison in primary CARE)
Principal Investigator: Richard Bergenstal, MD, Thomas Martens, MD
Study sponsor: Patient-Centered Outcomes Research Institute
Location: 10 select Primary Care Clinics across the HealthPartners network
Purpose of study: Your primary care clinic providers are partnering with the International Diabetes Center to invite you to join the GluCoCare study, a study looking at how using fingerstick blood glucose monitoring (BGM) compares to using continuous glucose monitoring (CGM) to manage type 2 diabetes in people using insulin.
In case you’re not familiar with a CGM, it is a device used to measure your glucose level every few minutes, 24 hours a day. CGM lets you see your current glucose level and shows you if your glucose is going up, down or staying steady. You can also see daily glucose patterns over time.
While it is known that controlling blood glucose is important in managing diabetes, especially when using insulin, it is not yet known which of the two ways to measure blood glucose is better. This important study will help people with type 2 diabetes know which method of measuring glucose is more helpful in improving glucose levels and decreasing the work of managing diabetes. We’re hoping you’ll partner with us to learn if using BGM or CGM is better to help manage blood glucose.
Inclusion Criteria:
This study is accepting individuals ages 18-75 who:
– Have type 2 diabetes
– Have a hemoglobin A1c 7.5-12
– Currently use insulin
– Are not currently using continuous glucose monitoring
– Currently receiving care at one of 30 clinics within the HealthPartners system
– Meet other study specific requirements
Participants will receive compensation for completed study visits up to a total of $250 if all visits are completed.
If you are interested in participating and would like to see if you are eligible, please click here to answer some eligibility questions.
Study Contact:
GluCoCare Team
(952) 967-5805
IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Medtronic
Location: International Diabetes Center
Purpose of study: The purpose of this study is to see how well the Minimed 780G insulin pump system works to automatically infuse insulin for control of glucose levels for people with type 2 diabetes who use insulin. This Medtronic MiniMed 780G system consists of an insulin pump, a glucose sensor, a transmitter, and a glucose meter. The system uses continuous glucose readings from the sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 2 diabetes. The MiniMed 780 System and related supplies are provided for use during the study at no cost to qualifying participants.
Involvement in the trial will include:
• Compensation for completed study visits
• Diabetes management and education, support and guidance by diabetes professionals
• Study-related medical care, including regular health checks and lab tests provided at no cost to you
Inclusion Criteria:
The study is accepting individuals ages 18-80 who:
– Have had type 2 diabetes for 2 years or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
MyDiabetes Study
Principal Investigator: Holly Willis, PhD, RDN, CDCES
Study sponsor: American Diabetes Association, Dexcom, Park Nicollet Foundation
Location: International Diabetes Center
Purpose of study: This study will test whether there is a difference between two different ways of helping someone learn how to use a continuous glucose monitor (CGM) and how that affects a person’s glucose. The CGM is a small device worn on your abdomen that allows you to see what your glucose is at any time of the day. People can use information from a CGM to help make choices about food, activity, and medication in a way that works for their diabetes.
All participants in the study will be provided with the Dexcom G6 CGM system. The system has a sensor that measures a person’s glucose level continuously and the glucose numbers can be seen on the person’s smartphone.
Participants will receive the following, at no cost:
• Study-related medical care including diabetes education and lab tests
• Dexcom G6 CGM systems for use during the study
• Payment for completed visits
To learn more, visit our site: https://redcap.link/qyd133pv.
For questions, email IDCResearch@parknicollet.com
or call 952-993-9605 and refer to the “MyDiabetes CGM study.”
Inclusion Criteria:
– Are age 18 or older
– Have type 2 diabetes
– Do NOT take insulin
– Have an A1C between 7.0%-10.0%
– Have never used a CGM, or have not used on recently
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Piqray CGM IIT: Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib (CBYL719A0US16T)
Principal Investigator: Dylan Zylla, MD, Richard Bergenstal, MD
Study sponsor: HealthPartners Institute
Location: HealthPartners Cancer Center at Regions Hospital, HealthPartners Frauenshuh Cancer Center
Phase of Study: II
Purpose of study: The purpose of the study is to characterize and understand the impact of alpelisib on glucose control in patients with breast cancer using Continuous Glucose Monitoring (CGM) and following a hyperglycemia prevention and management regimen.
Inclusion Criteria:
– Adults age 18+ with diagnosis of metastatic Breast cancer that are initiating treatment with Alpelisib.
– Must be willing to and comply with study visits and procedures.
– Must meet standard clinical criteria for utilizing Alpelisib, including Hormone-receptor positive/HER2 negative cancer with presence of PIK3CA mutation.
– Treating oncologist must plan to use Alpelisib until disease progression or unacceptable toxicity.
– Patient must receive cancer care with a HealthPartners Oncologist during Alpelisib treatment phase and must be willing to see IDC/HealthPartners Diabetes Education for diabetes management.
– Must have compatible smartphone, access to compatible smartphone, or ability to digitally upload information from Continuous Glucose Monitor (CGM), or to bring the reader in to the medical visit at least once a month for uploading data.
– Must have life expectancy of at least 3 months.
Exclusion Criteria:
– Has known history or allergy to skin-adhesive material, or previous cutaneous reaction to a continuous glucose monitor.
– Known currently uncontrolled diabetes, defined as most recent HbA1c over 10%, or history of DKA within 6 months prior to enrollment.
– Concurrent use of high-dose vitamin C, defined as more than 1g of oral vitamin C daily, or IV vitamin C infusions.
– Any concurrent severe, or uncontrolled condition that, in the opinion of the investigator, would cause safety risk, compromise protocol compliance, or contraindicate patient’s participation in the study.
Study Contact:
Alissa Gavenda, RN
(952) 992-5705
Alissa.Gavenda@ParkNicollet.com
Safety and Efficacy of the Omnipod® 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes (SECURE T2D)
Principal Investigator: Anders Carlson, MD
Study sponsor: Insulet
Location: International Diabetes Center
Purpose of study: This study will be testing an insulin delivery system in people who have type 2 diabetes. The system is called the Omnipod 5 System. The study is being done to find out if the treatment of type 2 diabetes works better with the Omnipod 5 compared to taking daily insulin injections. The system consists of a tubeless insulin pump (pod) that can deliver insulin for up to 3 days, an app installed on a controller or smart phone, and the Dexcom G6 Continuous Glucose Monitoring System® (CGM).
Inclusion Criteria:
The study is accepting individuals ages 18-75 who:
– Have type 2 diabetes and are using insulin
– Have an A1C < 12%
– Are willing to use the insulin pump system throughout the study
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Weight Loss Wizard: Patient Perspective Interviews (Weight Loss Wizard)
Principal Investigator: Patrick O’Connor, MD, MPH, MA
Study sponsor: NIH/NIDDK
Location: Enrolled participants do not need to travel
Purpose of study: The Weight Loss Wizard participant interview is supported by National Institutes of Health to gather input from patients about their experiences with talking to their primary care doctors about weight loss options. The information gathered will help guide design and content of a shared decision-making tool used at the point of care. The interview is being offered via phone or conference call to patients with Type 2 Diabetes.
Inclusion Criteria:
-Patients with Type 2 Diabetes
Exclusion Criteria:
-Previous metabolic bariatric surgery
Study Contact:
Center for Evaluation and Survey Research
(952) 967-6912
WeightLossWizard@HealthPartners.com
